Skip to content

Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts

Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03611465
Acronym
ATLAS
Enrollment
117
Registered
2018-08-02
Start date
2018-10-26
Completion date
2024-04-26
Last updated
2022-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Tachycardia

Keywords

Sudden cardiac death, Electrophysiologic exploration, Myocardial infarction

Brief summary

Aim of this study is to collect data from pace mapping performed in three groups of patients : patients presenting ventricular tachycardia and infarction history, patients presenting infarction history without presenting ventricular tachycardia, and in patients without structural heart disease.

Detailed description

Ventricular tachycardia (VT) represent an important problem in western countries. 350 000 deaths are attributable to ventricular arrhythmias in Europe every year. The gold standard treatment is to implant a cardiac defibrillator that will be able to stop arrhythmia by delivering pacing or internal shocks. In order to avoid internal shocks, ablation techniques have been developed, consisting in placing catheters in the left ventricle, to induce the VT, and then to perform a mapping of its circuit. Once this circuit is clearly defined, ablation of the critical part of the circuit, so called VT isthmus can be performed, using a radiofrequency power. One of the limitations of this technique is that it requires VT induction during the procedure, and that the VT lasts long enough to enable its mapping. Nancy University Hospital developed a technique using pace mapping to define the VT isthmus even when the VT is not sustained. The pace mapping technique enables to reveal conduction troubles in the studied ventricles, that correspond with the VT isthmus. During this study, the investigators will collect pace-mapping data from ventricles of patient presenting infarction history and VT, from patients with infarction history without VT, and from patients without ventricular pathology.

Interventions

OTHERPace-mapping

Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.

OTHERStandard pace-mapping examination

Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

There is no randomization. Patients are provided into 3 groups according to their pathology.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Presenting one of these conditions : * patients undergoing a VT ablation and myocardial infarction history * patients with myocardial infarction history without VT history * patients without myocardial infarction history but undergoing an invasive procedure in left atrium (atrial fibrillation or accessory pathway ablation)

Exclusion criteria

* pregnancy * LVEF (left ventricular ejection fraction ) \<20 % * hemorrhagic stroke history

Design outcomes

Primary

MeasureTime frameDescription
Complete electrophysiology datasets for each groupthe electrophysiological exploration is carried out the day after the patient's hospitalization and the datasets are generated just after removing the catheter from the patient, ie about 3 hours later the beginning of the explorationCollection of all complete electrophysiology datasets for each group. A data set consists of the electro-anatomical data generated by the Carto system and ECG data collected during topo-stimulation. Collection of all complete electrophysiology datasets for each group. A data set consists of the electro-anatomical data generated by the Carto system and ECG data collected during pace-mapping. It will be considered complete if 100 measurement points have been acquired (pace-mapping and ECG), covering all 17 segments of the left ventricle.

Countries

France

Contacts

Primary ContactJean-Marc SELLAL
jm.sellal@chru-nancy.fr0033 3 83 15 32 56

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026